

Expert consensus and evidence-based recommendations for the assessment of flow-mediated dilation in humans



Download Clinical Guidelines

Dick H.J. Thijssen^{1,2}, Rosa Maria Bruno ^{3,4*}, Anke C.C.M. van Mil^{1,2}, Sophie M. Holder¹, Francesco Faita⁴, Arno Greyling⁵, Peter L. Zock⁵, Stefano Taddei³, John E. Deanfield⁶, Thomas Luscher⁷, Daniel J. Green^{1,8}, and Lorenzo Ghiadoni³

¹Research Institute for Sport and Exercise Science, Liverpool John Moores University, Liverpool, UK; ²Department of Physiology, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands; ³Department of Clinical and Experimental Medicine, University of Pisa, Italy; ⁴Institute of Clinical Physiology, National Research Council, Via Moruzzi 1, 56124 Pisa, Italy; ⁵Department Nutrition & Health, Unilever Vlaardingen, 3133AT Vlaardingen, The Netherlands; ⁶Institute of Cardiovascular Sciences, University College of London, 1 St Martin le Grand, EC1A 4NP London, UK; ⁷Royal Brompton and Harefield Hospitals, London University Heart Center, Sydney Street, SW3 6NP, London, UK; and ⁸School of Human Sciences (Exercise and Sport Science), The University of Western Australia, Crawley, Western Australia, Perth 6009, Australia

Received 3 March 2018; revised 13 June 2018; editorial decision 21 January 2019; accepted 24 May 2019

Endothelial dysfunction is involved in the development of atherosclerosis, which precedes asymptomatic structural vascular alterations as well as clinical manifestations of cardiovascular disease (CVD). Endothelial function can be assessed non-invasively using the flow-mediated dilation (FMD) technique. Flow-mediated dilation represents an endothelium-dependent, largely nitric oxide (NO)-mediated dilatation of conduit arteries in response to an imposed increase in blood flow and shear stress. Flow-mediated dilation is affected by cardiovascular (CV) risk factors, relates to coronary artery endothelial function, and independently predicts CVD outcome. Accordingly, FMD is a tool for examining the pathophysiology of CVD and possibly identifying subjects at increased risk for future CV events. Moreover, it has merit in examining the acute and long-term impact of physiological and pharmacological interventions in humans. Despite concerns about its reproducibility, the available evidence shows that highly reliable FMD measurements can be achieved when specialized laboratories follow standardized protocols. For this purpose, updated expert consensus guidelines for the performance of FMD are presented, which are based on critical appraisal of novel technical approaches, development of analysis software, and studies exploring the physiological principles underlying the technique. Uniformity in FMD performance will (i) improve comparability between studies, (ii) contribute to construction of reference values, and (iii) offer an easy accessible and early marker of atherosclerosis that could complement clinical symptoms of structural arterial disease and facilitate early diagnosis and prediction of CVD outcomes.

Keywords

Flow-mediated dilation • Methodology • Cardiovascular disease • Brachial artery • Vascular function

Introduction

Cardiovascular disease (CVD) remains the world's leading cause of morbidity and mortality.^{1,2} Development of CVD starts in early childhood and progresses silently for many years,³ ultimately resulting in angina, myocardial infarction, or ischaemic stroke. The endothelium plays a central role in the process of atherosclerosis from the first to the advanced stages. Due to its strategic anatomical position, it is highly responsive to detect various haemodynamic stimuli (e.g. shear

stress, circumferential wall strain)⁴ and regulates vascular tone, growth, adhesion, and coagulation in an endocrine-paracrine manner.⁵ Not surprisingly, impairment of endothelial function precedes development of atherosclerosis, evident by thickening of the arterial wall and plaque formation.^{6–9} Endothelial dysfunction is also linked to inflammatory changes within atherosclerotic plaques, leading to plaque vulnerability and, subsequently, increased risk for clinical events.^{3,10} The intrinsic link between inflammation and endothelial dysfunction is well-established.^{11,12}

The opinions expressed in this article are not necessarily those of the Editors of the *European Heart Journal* or of the European Society of Cardiology.

* Corresponding author. Tel: +39 050 992914/050 992711, Fax: +39 050 992409, Email: rosamaria.bruno@unipi.it

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2019. For permissions, please email: journals.permissions@oup.com.

Several (non-)invasive tools to examine endothelial function have been developed. These techniques provide insight into the pathophysiology of atherosclerosis and CVD, but may also predict cardiovascular (CV) events. The present article discusses flow-mediated dilation (FMD), which represents a popular and widely used non-invasive tool for examining peripheral artery endothelium-dependent dilation, originally introduced in 1992.¹³ Briefly, this technique adopts ultrasound to examine changes in brachial artery diameter in response to ischaemia (typically 5 min), induced by inflating a blood pressure cuff distal from the imaged artery around the forearm to supra-systolic level. Importantly, substantial variation in performing the FMD is present, which impairs its reproducibility and comparison between studies. First, we will briefly discuss techniques utilized to assess endothelial (dys)function, and specifically focus on the clinical value of FMD. Subsequently, we will provide updated expert consensus guidelines for the performance of FMD, which are based on critical appraisal of novel technical advances, development of analysis software, and studies exploring physiological principles underlying the technique.

Vascular reactivity tests

Endothelial dysfunction, which is characterized by reduced nitric oxide (NO) availability,¹⁴ was originally demonstrated by infusing acetylcholine in atherosclerotic coronary arteries.¹⁵ Since this technique is invasive and not widely applicable, less invasive studies in the peripheral circulation have been then introduced ([Supplementary material online, Table](#)). A technique with methodological similarities to intra-coronary infusion involves venous plethysmography, typically of the forearm. After arterial cannulation, forearm blood flow changes after infusion of vasoactive substances modulating NO-release are measured. Alternatively, non-invasive techniques include peripheral arterial tonometry (PAT) and FMD, both measuring vasodilator responses after transient ischaemia. Whereas FMD examines macrovascular endothelial function of the brachial artery, PAT may represent a measure of finger microvascular function. Techniques have their specific advantages and disadvantages ([Supplementary material online, Table](#)), as extensively reviewed elsewhere.¹⁴ Importantly, non-invasive techniques have been validated against coronary endothelial function, providing the pathophysiological basis for the predictive value of these tests for CVD.^{16,17}

Clinical value of flow-mediated dilation

Association with cardiovascular disease prognosis

Impaired FMD has been associated with conditions predisposing to atherosclerosis and CVD, representing an early step in developing subclinical target organ damage and late clinical events.¹⁸ Brachial FMD is associated with carotid intima-media thickness progression in a population free of CVD⁷ and in hypertensive, postmenopausal women.¹⁹ In a 3-year follow-up study in hypertensive patients, FMD-predicted target organ damage progression (including carotid intima-media thickness, pulse wave velocity, albuminuria, and left ventricular hypertrophy), even after adjustment for known risk factors.²⁰

Furthermore, impaired FMD represents an independent predictor of in-stent stenosis after single-vessel coronary interventions.²¹

Several studies have demonstrated the prognostic value of brachial artery FMD for CV events ([Table 1](#)).^{22–25} Meta-analyses indicate a significant 8–13% lower risk of CV events per percent point increase in brachial artery FMD (e.g. from 5% to 6% dilation, [Figure 1](#)). This reduction was relevant both in high- and low-risk populations,^{22,25} though appeared larger in patients with established CVD.^{23,24} Except for one meta-analysis,²⁴ the overall estimated study quality did not significantly influence FMD predictive value.^{22,23,25}

One meta-analysis of 14 studies assessed the influence of the site of the cuff position, which was either placed distal (i.e. forearm) or proximal (i.e. arm) from the imaged artery ([Table 1](#)).²⁶ This study found that the predictive capacity of the FMD using distal cuff position did not differ from using FMD with proximal cuff positioning. This was confirmed in a later meta-analysis that included a larger number of studies.²⁴

Incremental value of flow-mediated dilation over traditional cardiovascular risk factors

Flow-mediated dilation has failed to demonstrate an added value to classical CV risk factors in terms of discrimination and net reclassification.²⁷ In the Multi-Ethnic Study of Atherosclerosis (MESA) cohort of intermediate-risk individuals, FMD did not increase discriminative power or net reclassification index of risk compared to the Framingham Risk Score.²⁸ However, the low reproducibility of the FMD in the MESA study, in which the intra-class correlation coefficient was 0.54²⁸ (worse than other studies in healthy volunteers^{29,30} and CVD patients^{30,31}), may have contributed to these negative findings. Alternatively, FMD may simply reflect compound risk burden that impacts upon vessel function and hence may not provide incremental risk prediction. A recent position paper by the *European Society of Cardiology Working Group on Peripheral Circulation*³² concluded that FMD is principally a valuable research tool. Moreover, authors stated that, partly because poor standardization between laboratories and lack of guideline adherence, FMD is currently not recommended for the assessment of CV risk, with evidence grading remaining at III, in accordance with other guidelines.^{33,34}

Clinical value of long-term changes in flow-mediated dilation

Longer-term improvement in FMD may have a prognostic implication.³⁵ Therefore, assessment of FMD in interventional trials could represent a surrogate endpoint, especially since FMD responds rapidly to therapies, allowing identification and selection of new drugs or bioactive substances.³⁶ The lack of improvement in FMD might identify 'non-responder' patients, who might be suitable for more intensive or new therapeutic approaches. For example, improvement in FMD following 6 months of antihypertensive therapy was associated with a more favourable prognosis for CV events in hypertensive postmenopausal women.³⁷ Furthermore, persistent impairment in FMD after optimized risk reduction therapy represents an independent predictor of CV events in patients with coronary artery disease.³⁸ Finally, a persistently impaired FMD, after optimized therapy in heart failure, independently predicted cardiac events.³⁹ These studies

Table 1 Summary of meta-analyses that included studies on predictive value of flow-mediated dilation on cardiovascular disease prognosis

Study	Number of studies (no CVD/CVD populations)	Number of subjects	Age range (years)	Follow-up (months)	Pooled CVD risk (RR ^a ; 95% CI)
Inaba <i>et al.</i> ²²	15 (9/4)	5547	51–78	6–93	0.87; 0.83–0.91
Green, <i>et al.</i> ²⁶	14 (9/5)	8318	51–79	6–93	0.83; 0.78–0.88 ^b 0.91; 0.87–0.69 ^c
Ras <i>et al.</i> ²³	23 (15/8)	14753	46–79	12–96	0.92; 0.88–0.95
Xu <i>et al.</i> ²⁵	32 (19/13)	15191	47–73	6–115	0.90; 0.88–0.92
Matsuzawa <i>et al.</i> ²⁴	35 (22/13)	17280	46–79	6–115	0.88; 0.84–0.91

CI, confidence interval; CVD, cardiovascular disease; FMD, flow-mediated dilation; RR, relative risk.

^aPer 1% higher FMD.

^bDistal cuff occlusion.

^cProximal cuff occlusion.

support the potential use of repeated assessment of FMD, rather than a single measure, to predict future CV events.

Potential value of short-term changes in flow-mediated dilation

Many studies have examined short-term changes in FMD, ranging from a few hours, to several days, and up to months. In these randomized trials, FMD was selected as the primary outcome measure to investigate the potential protective impact of (non-)pharmacological therapies.^{36,40–42} Increase in FMD in response to (non-)pharmacological substances may translate to long-term improvements in endothelial function and protection against atherosclerosis and/or CVD. The relative simplicity of the design and the ability to perform reproducible, repeated measurements explain the popularity of examining changes in FMD in these studies.¹⁴

In summary, a biomarker is only useful for CV risk prediction when it adds incremental information to traditional CV risk factors, being independently associated with outcomes, and also improving discrimination, calibration and net reclassification of risk, especially in those at intermediate risk.⁴³ Current evidence on these issues pertaining to FMD is incomplete. In part, this seems related to the diversity between studies in adherence to expert consensus guidelines. Moreover, reference values are yet to be established and are necessary for widespread applicability. Nonetheless, FMD has proven beneficial when examining (short-term) changes to evaluate the effects of (non-)pharmacological interventions.

Ultrasound assessment: technical requirements and common mistakes

Diameter and velocity assessment

Flow-mediated dilation is typically examined in the brachial artery (diameter 3–5 mm). Longitudinal images of the brachial artery are taken using high-resolution B-mode ultrasound, usually with an ultrasound probe of 7.5–12 MHz. Studies have also examined smaller (e.g. radial artery: diameter 1.5–3 mm) or larger sized arteries (e.g.

superficial femoral artery: diameter 5–7 mm, popliteal artery: diameter 4–6 mm). Changes in resolution may be required to optimize B-mode images in arteries that lie at differing depths. A key challenge with B-mode imaging is to identify clear vascular boundaries, i.e. the double lines of Pignoli (*Figure 2*).^{44–46} A reasonable approach involves obtaining an image characterized by a single echogenic layer, representing the brachial artery wall-lumen interface. Since diameter is a key determinant of FMD, the modality of measurement applied may influence results and, under all circumstances, should be kept the same throughout the experiment. Special attention should be paid to perform adequate scanning of the baseline diameter. More specifically, tangential scanning is a common error and results in underestimation of the true brachial artery diameter. Recent technological advances, which adopt an H-shaped probe capturing two short-axis and one long-axis for automatic probe position correction, may overcome this crucial limitation.⁴⁷

Simultaneous live acquisition of the pulsed-wave Doppler velocity is recommended, given the importance of shear stress as the eliciting stimulus for dilation.^{48–50} An important limitation of this approach is that the same transducer is employed to detect Doppler velocity and arterial diameter, which have competing requirements for optimal data acquisition. B-mode echoes are of greater intensity with perpendicular insonation of the ultrasound beam (90°), whereas optimal pulse-waved Doppler signals require parallel incidence with the direction of blood flow (ideally 0°, *Figure 2*).^{51–53} Therefore, a compromise must be reached to uphold fundamental principles and assumptions for both modalities.⁵³ The error linked to incorrect estimation of insonation angle increases exponentially with angles greater than 60°. ^{51–53} Therefore, we recommend an insonation angle of <60–70° (which is the best achievable angle with standard ultrasound machines), which should be kept constant and reported in the manuscript.

Finally, the sample volume used for pulsed-wave Doppler should be considered. Since measurements settings of the width of the sample volume vary between laboratories and impact upon the analysis of the velocity signal (see Analysis of the Velocity Signal section), we recommend to maintain consistency in methods within studies, and in particular for repeated tests within subjects.




Figure 1 (A) Schematic presentation of diameter and shear stress (or rate) responses before and after a 5-min ischaemic stimulus applied distally to the forearm. (B) Representative diameter (upper panel) and velocity (lower panel) data from a healthy person before and after the 5-min ischaemic stimulus. (C) Representative diameter (upper panel) and velocity (lower panel) data from a person with endothelial dysfunction before and after the 5-min ischaemic stimulus.

Analysis of the velocity signal

Duplex ultrasound-derived velocity and diameter data are both required for calculating shear stress, the eliciting stimulus for artery dilation during FMD. Although the increase in shear stress is the physiological stimulus for dilation, most studies present shear rate, as it is assumed that blood viscosity does not differ between participants and/or groups.^{50,54,55} Since no uniformity exists in the calculation of

shear rate,⁵⁶ calculations must be described in the manuscript. Two different formulas have been suggested, according to the sample volume size and placement:

- Shear rate = $8 \times \text{mean blood velocity} / \text{internal diameter}$; for large, centred sample volume;
- Shear rate = $4 \times \text{mean blood velocity} / \text{internal diameter}$; for small, centred sample volume.




Figure 2 Experimental set up for the performance of the brachial artery flow-mediated dilation. (A) Position of the cuff and ultrasound probe placed on the upper arm. (B) Screen shot of a representative B-mode image of the diameter and Doppler blood flow velocity. (C) Wall tracking software to perform (semi)automated analysis. (D) Output generated by the analysis software to enable calculation of the flow-mediated dilation.

A clear description must also be provided for the calculation of velocity. Mean velocity can be estimated by taking half of the *peak velocity* (i.e. fastest moving blood cells in the centre of the vessel) or the *intensity weighted mean velocity* (i.e. mean velocity from all Doppler shifts across the vessel).⁵² Although both methods seem valid, they cannot be used interchangeably.⁵⁷

Maintaining the optimal image: probe-holder vs. hand-held

Another common mistake is inconsistency in scanning the same portion of the artery during repeated measurements, or throughout a single FMD. Therefore, anatomical landmarks should be identified and recorded and/or the distance between the elbow crease and ultrasound probe should be recorded (or photographed). The position of the subject (related to the arm and hand), but also cuff size and position (see Protocol: Cuff Position section) should be also recorded and standardized.⁵⁸


To further ensure optimal image throughout the FMD-procedure, a probe-holding device can be useful.^{29,58,59} A stereotactic adjustable probe-holding device allows adjustment of probe position during the test, ensuring that the same scan is maintained throughout the study.¹⁸ Subject movement can also be compensated for when the probe hand-held, assuming an experienced sonographer. In a recent systematic review of studies that examined the reproducibility of the FMD, the use of a probe-holding device was associated with a higher

FMD reproducibility.⁶⁰ However, another recent study pooling repeated measurements from different centres found that reproducibility is not affected by a probe-holder device, when experienced laboratories perform FMD following strict guidelines.³⁰ It cannot be excluded that other differences between laboratories may explain these findings. Nevertheless, a probe-holding device is a cheap, easily obtainable tool. Because it may facilitate FMD testing for inexperienced operators and increase accuracy, a probe-holder device is recommended, especially for less experienced laboratories.

Practical considerations, study protocol, and data analysis

Subject preparation and environmental influences

Subject preparation is important in the valid and reproducible assessment of the FMD, with many studies failing to control for these factors and/or failing to report on their procedures in sufficient detail (*Take home figure*). Several subject-related factors can influence FMD, including food, alcohol, smoking, supplements, drugs, physical activity, and mental stress.^{61–64} While some factors directly impact stimulated NO-release, others, such as acute physical exercise,⁶² modify baseline vasomotor tone (and therefore baseline diameter).⁴ To minimize their effect, it is strongly recommended that



Take home figure Pictorial summary of the main recommendations for FMD evaluation in humans.

prior to FMD examination, subjects are fasted (>6 h), avoid exercise (>24 h), and refrain from caffeine, vitamin C, polyphenols, alcohol, and supplements known to affect the CV system for a consistent period of time (typically >12 h) (Table 2). Smokers must refrain from smoking for a standardized period (preferably >6 h). When examining patient groups taking drugs, we recommend waiting 4 times the half-life of the drug. If drug intake cannot be avoided, examination should be performed after a consistent and standardized time.⁵⁹ Since mental stress affects FMD,^{64,66} testing must be performed in a quiet, temperature-controlled room after a standardized period of supine rest of >10–15 min. Acute intense mental stress can cause prolonged (up to 90 min) impairment in FMD,⁶⁷ but its confounding effect can be hardly controlled or eliminated. Premenopausal women should be examined in a standardized phase of the menstrual cycle, since hormonal changes can affect FMD.⁶⁸ Vascular function in humans, including that assessed by FMD,⁶⁹ demonstrates a diurnal variation. This implies that the time of the day of FMD should be standardized and reported, especially when performing repeated measures. Other environmental factors that may affect FMD are outdoor temperature,⁷⁰ seasonality,⁷¹ and air pollution.⁷² However, because of practical reasons, these factors should not be considered as limiting when ideal conditions cannot be achieved.

Study protocol

Protocol: cuff position

Placement of the occlusion cuff importantly alters the magnitude,⁷³ duration,^{73,74} nature,⁷⁵ and possibly the clinical relevance²⁶ of the dilator response. Originally, Celermajer et al.¹³ examined brachial artery FMD with the occlusion cuff placed around the forearm, distal to the ultrasound probe (Take home figure). Standardizing cuff position is of crucial importance for valid comparisons between studies, since occlusion of a smaller volume (i.e. placement towards the wrist) or larger volume of tissue (i.e. cuff occlusion around the upper arm) leads to either a markedly attenuated diameter⁵⁸ or an enhanced^{73,76} shear stress response.

Some have supported the placement of the occlusion cuff above the imaged artery,⁷⁴ with the main argument that the larger dilator response⁷⁷ achieved by occluding a larger area may improve FMD discriminative power. One analysis found no significant differences in prognostic value between studies that adopted distal vs. proximal cuff position.²⁶ Furthermore, some limitations of proximal cuff inflation must be considered. First, scanning the brachial artery during this procedure is challenging, since the artery can collapse and/or tissue movements can worsen image quality. Secondly, the dilator response with proximal cuff position is largely mediated through vasoactive substances other than NO.⁶¹ A meta-analysis⁷⁵ found that the dilation in response to distal cuff occlusion is ~70% NO-mediated, whereas proximal cuff

Table 2 Recommendations for flow-mediated dilation assessment to examine a largely nitric oxide-mediated, endothelium-dependent vasodilation of a conduit artery

Methodological and technical guidelines	Required
Subject preparation	
Rest in a quiet, preferably darkened room for a period of 10–15 min prior to assessment.	1
Supine posture (i.e. the imaged artery should be around heart level).	1
Testing times must be standardized to avoid diurnal variation, and for multiple tests, all are to be conducted at a similar time of day	1
Subjects must be fasted for ≥ 6 h	2
Avoid exercise for ≥ 24 h, alcohol or food/drinks that contain caffeine or are rich in polyphenols for ≥ 12 h	2
No smoking or any tobacco consumption prior to measurement (>6 h)	2
Careful history should be taken regarding the use/timing of any drugs. Drug withdrawal may be required, but this depends on the protocol and is not always feasible (in patients) or required	2
Premenopausal women should be assessed in standardized part of the menstrual cycle (especially when performing repeated measures) or menstrual phase should be annotated.	2
Protocol	
Baseline diameter must be examined before cuff inflation for a period of >30 s	1
Present absolute baseline diameter in Results section	1
Cuff must be placed distal to the imaged artery, with cuff pressure exceeding systolic pressure with >50 mmHg and inflated for 5 min	1
Post-deflation diameter should be monitored continuously from deflation for ≥ 3 min	1
Endothelium-independent vasodilation should be tested and GTN dose should be reported	1
Sublingual administration of 25 μ g is suggested	3
Technique	
Continuous measurement of velocity and diameter using simultaneous live duplex ultrasound	1
B-mode images with a linear probe of ≥ 7.5 MHz should be used (and report probe details). The highest MHz available should be used, given tissue depth considerations	1
Blood velocity assessed using an insonation equal to 60 – 70° or less	1
Use the same angle for blood flow velocity within a study and study group (and report angle)	1
Analysis	
Use continuous edge-detection and wall tracking software	1
Automated mathematical algorithms should be used to calculate the peak diameter	1
Present the baseline diameter	1
Present the FMD-response in absolute (in mm) and relative (in %) change	1
Present the relevant shear rate stimulus (area-under-the-curve or peak shear)	2
Off-line analysis is performed by a blinded observer	3
Operator-dependent factors	
Sufficient training of sonographer (recommended levels of reproducibility: $<2\%$ coefficient of variation for diameter, $<15\%$ coefficient of variation for FMD in consecutive scans)	1
Maintain sonographer experience	1
A stereotactic probe-holder is recommended for less experienced laboratories	2

Based on previous work,⁶⁵ the right column indicates the level of requirement for specific recommendation: mandatory (1), highly recommended (2), and recommended when possible (3).

placement is only $\sim 30\%$ NO-mediated. These differences between studies are confirmed by direct comparisons of distal vs. proximal cuff position in the same individual.⁷⁴ This is mechanistically important, because several studies specifically aim to study the NO-dependent pathway, given its established importance in the process of atherosclerosis. Thus, strict standardization of distal cuff occlusion (i.e. below the imaged artery) is recommended to ensure maximal dependence of the dilator response on endothelium-derived NO.

Protocol: baseline diameter

The FMD-response is typically expressed as the relative change in post-hyperaemia diameter from baseline. As a direct consequence

and limitation, the FMD is a function of the degree of responsiveness to stimuli, but also of baseline vasomotor tone and structural remodelling. Correct assessment of baseline diameter is therefore of crucial importance and implies the removal of potential factors influencing both baseline diameter and vasomotor tone (see Subject Preparation and Environmental Influences section), but also practical (Diameter and Velocity Assessment section + this section) and statistical procedures (Shear Stimulus: Normalization for flow-mediated dilation Stimulus section + this section) linked to baseline diameter.

Most studies use the pre-inflation diameter to calculate the FMD, in line with the classic approach¹³ and previous FMD-guidelines.^{58,59,61} It is recommended that pre-inflation diameter should be

recorded for 1 min, with a minimum of 30 s.⁶¹ The end-of-ischæmia diameter has been also proposed as the baseline diameter for FMD calculation. However, 'low-flow' state during distal cuff occlusion may lead to artery constriction, though this phenomenon appears to be evident mostly in the radial^{78–80} rather than in the brachial artery.^{49,81–83} Conversely, one study showed that brachial artery diameter during cuff inflation was significantly larger than that assessed pre-inflation, leading to a lower FMD, an effect not present in older groups.⁸³ Based on these between-group differences, we recommend using pre-occlusion diameters as the baseline value so that the differential impacts of cuff occlusion on the baseline artery diameter are avoided.

Because FMD is defined as increase in diameter after occlusion, baseline diameter is strongly and inversely related with FMD.^{13,84,85} This relation has several important implications for comparing groups that differ in baseline diameter (e.g. age, CVD),^{86,87} and for interpretation of studies with interventions that may affect resting diameter (e.g. exercise training).⁴ Atkinson et al.⁸⁸ found that the FMD% does not accurately scale for inter-individual differences in baseline diameter but overestimated endothelial function for low baseline diameters and vice versa, thus proposed to adopt allometric scaling, a statistical method to account for the relationship between baseline and peak diameter.⁸⁴ The use of allometric scaling, however, is limited by its inability to adjust FMD values at an individual level.

Protocol: duration and magnitude of cuff occlusion

The original 5-min duration of cuff occlusion remains the most frequently used protocol. Shorter periods lead to negligible dilation,⁸⁹ whilst longer periods lead to larger blood flow and diameter responses, but may be less tolerable for volunteers.⁷³ Since the nature of dilation changes with longer periods of occlusion,⁷⁶ we recommend using a 5-min occlusion period.

Whilst a majority of studies use a pre-defined cuff occlusion pressure (typically between 200 and 300 mmHg), it is important that cuff pressure should exceed >50 mmHg above systolic pressure to prevent arterial inflow. In our experience, the procedure is generally well tolerated and drop-out due to discomfort is unusual, though no studies are available in literature specifically dealing with this aspect. A common-sense recommendation to minimize subject discomfort is to use a smaller-sized (5 cm), paediatric cuff instead of a standard (12 cm) cuff. In addition, providing clear information about the study protocol and FMD-procedure is essential.

Protocol: post-deflation measurements

In the first studies using the FMD approach, peak diameter was examined using static frames at or around 60-s post-deflation.¹³ During the past decade, several studies found that this approach (or using pre-determined time-windows) can significantly underestimate the true peak dilation.⁹⁰ More importantly, the timing of the peak dilation may differ between groups⁹⁰ or after interventions.^{90–93} Therefore, to ensure successful capture of the true peak brachial artery diameter, guidelines support continuous examination up to 180-s post-deflation.

Endothelial function is increasingly examined in conduit arteries other than the brachial artery. However, the nature of the diameter responses in other arteries may differ from that in the brachial artery. For example, the content of endothelial NO synthase is

heterogeneous throughout the arterial tree.⁹⁴ This may impact upon the relative contribution of NO to the dilator response. In addition, lower limb arteries show a significantly delayed peak dilation compared to those in the arms.⁹⁵ This means that the 3-min post-deflation time window may not be long enough for all arteries. These potential differences must be considered when performing and interpreting the FMD in other conduit arteries.

Identification of the peak diameter

Early studies applied electrocardiogram (ECG)-based-gated analysis to identify peak diameter.⁵⁹ This approach assesses the diameter at the onset of R-waves (i.e. end-diastole), which limits the influence of arterial compliance on the assessment of the diameter. In the past decade, driven by the technical possibility and recognition of its relevance, studies typically adopted continuous data analysis of the diameter across the cardiac cycle. Continuous data analysis shows good agreement with ECG-gated analysis^{96,97} and is more time-efficient.⁹⁷ The accuracy and availability of this procedure makes ECG-gating no longer mandatory for determining peak artery diameter.

Shear stimulus

Shear stimulus: importance for flow-mediated dilation

Although the terminology of FMD suggests that dilation is flow mediated, physiological work demonstrates that it is rather mediated through the post-deflation increase in shear stress.⁴⁸ Studies that adopted within-subject manipulation of the post-deflation shear stress stimulus revealed that the relation between shear stress and dilation is dose-dependent.^{48,49,98,99} This fits with landmark studies^{100,101} demonstrating the importance of shear stress in mediating endothelium-dependent dilation. Pyke and Tschakovsky⁴⁹ suggested that the total, rather than peak shear stress, is more important in mediating conduit artery dilation.⁴⁹ This finding was later confirmed by others.⁵⁰ These studies show physiological and mechanistic basis for the continuous recording of both conduit artery diameter and velocity (Figure 1).

Shear stimulus: normalization for flow-mediated dilation stimulus

Based on the importance of shear stress as the eliciting stimulus, and also the assumption that within-/between-subject variation in FMD-responses relate to the magnitude of reactive hyperaemia, studies have used different approaches to account for the shear stress stimulus. An early approach involved 'simple' ratio normalization by dividing FMD by shear rate stimulus.^{50,82,102} However, this approach tends to violate important statistical assumptions, being (i) the relationship between both parameters is linear, (ii) the intercept for the regression slope of this relationship is zero, (iii) data (including residuals) are normally distributed, (iv) variances are similar between groups, and (v) the ratio does not lead to spurious correlations with other variables.¹⁰³ Whilst acceptable-to-good relation between the shear rate stimulus and FMD is present within subjects,^{48–50,89,99,104} studies examining this relation between subjects found a weak⁹⁵ or absent¹⁰⁵ relation. Whilst this does not invalidate the role of shear stress as the dilator stimulus, it indicates that FMD variability cannot be simply controlled for by ratio normalization.¹⁰³

Studies have also explored other strategies to statistically correct the FMD-response for the shear stress stimulus, such as including shear rate as a covariate in an analysis of covariance.^{103,106,107} Covariate in an analysis of covariance results, however, could be misleading if the covariate (i.e. shear rate), is related to the independent and/or outcome variable (e.g. age, sex, baseline diameter, and FMD). However, since calculation of shear rate importantly depends on baseline diameter, shear rate normalization may not be needed if the FMD is scaled properly to baseline diameter using the previously mentioned allometric scaling.¹⁰⁸

Taken together, it is currently not clear which statistical strategy is preferred to account for the eliciting shear rate stimulus in the FMD response. Ratio-normalization seems statistically flawed, whilst too many questions remain present around validity, practicality and potential clinical importance of statistical correction for the shear rate stimulus. It is recommended to report the relevant shear rate stimulus, i.e. shear area-under-the-curve up to the peak diameter. Reporting the shear stress stimulus may also be clinically relevant because the post-occlusion hyperaemia is strongly related to CV risk, and may have prognostic value for future CV events.^{109–112}

Analysis: Blinding, edge-detection, and wall-tracking

Early FMD research relied on a manual approach to assess diameter change through visual inspection and calipers placement.^{13,113} This method is highly operator-dependent, carries risk of observer error and is time-consuming.^{45,114–117} Recent years, software systems for automatic diameter measurement have been developed. This represents a time-efficient approach and has limited operator-related errors and bias. More importantly, intra-observer variation is significantly lower with automated analysis compared to the classic manual technique.^{45,46,114,116–118}

Automatic wall tracking algorithms belong to two main categories according to the input signal: radiofrequency (RF) backscattering or grey scale speckle pixel intensities. In general, RF-based algorithms are mono-dimensional, with raw data processed in a single vertical line of view, while speckle tracking is applied on large bi-dimensional regions of interest. Previously, the RF-system was considered more accurate due to higher axial spatial resolution, but this comes at the cost of assessing a single arterial diameter site (analogous to the use of a single caliper dimension). Pixel density systems allow for multiple diameter assessments within a given frame, whilst recent speckle tracking systems have also overcome the spatial resolution limitation.¹¹⁹

Adoption of automatic software overcomes methodological issues linked to the use of manual calipers. Since maximal brachial vasodilation is 0.1–0.4 mm and the typical resolving power of manual calipers of 0.1 mm, the manual approach is likely to introduce significant within- and between-observer error. Manual measurements also have a low number of samples per time-frame, whilst a more detailed time-course of changes in diameter is desirable, especially to identify the true peak diameter.⁹⁰ Among potential advantages offered by automatic systems, real-time analysis allows for instantaneous feedback on scan quality and rapid adjustments in response to patient/probe movements. This real-time feedback may help the sonographer to optimize image quality. Another potential advantage is to immediately

identify technical failure of the measurement, with the possibility to repeat the FMD after an adequate resting time.

An additional advantage of automated systems is their ability to use both ECG-gated and non-gated ultrasound images without affecting the FMD results.⁹⁶ This can help to keep the experimental setup as simple as possible, for example, by adopting a cheaper entry-level ultrasound device without ECG synchronization capability. Software systems for automatic FMD evaluation should be usable and user-friendly, but also should provide options to view and record different parameters (i.e. shear rate). Furthermore, the high throughput of data, ease of use and other technical features (e.g. real-time feedback, overlay of edge detector output with B-Mode) may help adequate training of the operator. Finally, any new automatic system must be validated in appropriate populations before introducing its use in laboratories.^{45,120}

Summary and future directions

In conclusion, strong evidence supports the following methodologies: placement of a lower cuff occlusion and use of continuous diameter monitoring by automatic edge-detections systems. Furthermore, the general study protocol, subject preparation and lab requirements are well defined. It remains uncertain whether and how to correct FMD for the shear stimulus and/or baseline diameter. The pathophysiological significance and clinical relevance of additional parameters, such as flow-mediated constriction and reactive hyperaemia as a marker of microcirculatory function, are still matter of debate and require further investigation.

Reproducibility of flow-mediated dilation measurements

Several studies have examined FMD reproducibility. However, these have been performed with widely varying adherence to FMD-guidelines. After pooling the results of seven centres that strictly followed FMD-guidelines, including optimal training of operators and monitoring, Ghiadoni *et al.*²⁹ found that FMD in healthy volunteers is highly reproducible among centres (coefficient of variation 11.6–16.1%). Data from the dal-VESSEL trial also showed reproducible results in 19 laboratories after standardized training in patients with CVD (coefficient of variation 15.8–17.5%).³¹ More recently, Greyling *et al.*¹²¹ designed a tool to evaluate adherence to FMD expert consensus guidelines. Subsequently, a meta-analysis was performed to assess the relation between degree of adherence and reproducibility of the FMD.⁶⁰ Not surprisingly, stricter adherence to guidelines was related with markedly less measurement error in brachial artery FMD. This work highlights that strictly following contemporary guidelines leads to highly reproducible results.

Factors influencing reproducibility: group and methodology differences

Guidelines for FMD measurement cannot cover and eliminate all sources of measurement variations and error. Understanding of these factors is important for designing studies on FMD (e.g. sample size calculations). van Mil *et al.*³⁰ recently performed analysis of 672 repeated FMD measurements that were collected after strictly following contemporary guidelines. High reproducibility was found in

healthy subjects (9.3%), whilst regression models several factors that contributed to variations in reproducibility (see below).

Subject characteristics

Subjects with older age, hypertension, or dyslipidaemia show a larger variability in FMD.^{29–31} This supports earlier findings in that CV risk factors impair FMD reproducibility.⁶⁵ An explanation for the larger variation in high-risk subjects may relate to the lower baseline FMD% typically observed in these populations.^{58,122,123} Indeed, van Mil et al.⁶⁵ demonstrated that a lower FMD% explained part of the higher variability in FMD with older age and dyslipidaemia. Differences in vascular structure and compliance may also contribute to this higher variability¹²⁴ and finally, not all subjects may be equally susceptible to the effects of CV risk factors at the endothelial level.

Methodological characteristics (time between measurements)

Longer time periods between subsequent FMD measurements leads to larger variation.^{29,30} Nonetheless, when strictly following guidelines and controlling for potential physiological factors,²⁹ it is possible to detect FMD changes, induced by interventions, over time with a relatively low sample size. Current data on within- and between-subject variability justify the use of FMD as an outcome measure in short-to-medium-term studies to evaluate (non)pharmacological interventions in humans.

Methodological factors (lab experience)

Possibly the most important methodological source of variability in the FMD is proper operator training. Guidance and training by expert colleagues seems crucial, since lower variability is present in more experienced laboratories.³⁰ Although the need of experience in scanning is mentioned by previous guidelines,^{58,59,61} it is difficult to quantify 'proper training'. No study specifically aimed at quantifying the appropriate duration of the training, like what was done for carotid intima-media thickness.¹²⁵ Corretti et al.⁵⁹ suggested that >100 scans/year are required to maintain competency. However, there was no mention of the training required before performing FMD measurements. Two independent consortia adopted a formal training for sonographers: sonographers were qualified for measurements when the CV for repeated scans were <2% for brachial artery diameter and <15% for FMD.^{29,31} Since FMD variability seems larger in individuals with CV risk,^{29,31} operator training might be longer depending on the study population enrolled. Both aforementioned studies showed excellent reproducibility among centres, suggesting that specialized training is feasible and successful. We therefore recommend that all studies on FMD should report details on preparation and training of the sonographers, along with the observed variability in their FMD measurements.

Endothelium-independent dilation

Pathophysiology and clinical relevance

The degree of FMD can also be influenced by the functionality of vascular smooth muscle (VSM) cells.¹²⁶ Any functional defect in VSM cells reduces their capacity to respond to NO, whilst a compensatory

increased VSM response may be present in endothelial dysfunction.^{127,128} In any case, it is recommended that the studies on endothelium-dependent vasodilation also determine the extent of any coexistent endothelium-independent dysfunction. Although this recommendation was already present in previous FMD-guidelines,⁵⁹ a standardized protocol has not been clearly defined yet.

Clinical determinants of VSM function are not fully understood. In a large Japanese cohort, brachial artery dilation to sublingual glyceryl trinitrate (GTN) was correlated with most classical CV risk factors and represented an independent determinant of FMD.¹²⁹ Conversely, a meta-analysis reported micro-, but not macrovascular, impairment of VSM in Type 2 diabetic patients.¹³⁰ Since the brachial artery was studied in only 12 out of the 31 studies, this subgroup analysis is likely underpowered. Furthermore, some studies found a relation between brachial artery GTN-responses and lack of nocturnal blood pressure fall,¹³¹ coronary artery calcium,¹³² and microalbuminuria.¹³³ Although GTN-responses show a relationship with Framingham Risk score,¹²⁹ only few prospective studies investigated the relation between this response and CVD events.^{134,135} Thus, the prognostic value of the GTN-response remains mostly inconclusive.^{134,135} Finally, the doses typically used in these studies induce near-maximal dilation,⁷³ hence the GTN-responses may be a structural index rather than a functional one.

Dose, technique, and administration of exogenous nitrates

Many research centres use sublingual GTN 400 µg, the lowest marketed dose in many countries. Administration of GTN via a sublingual spray leads to a larger and faster response than by tablet administration.¹³⁶ Lower dosages (25 µg) of GTN were later introduced¹³⁷ and recommended in the 2005 ESH-statement.¹³⁸ The rationale for lower dosages is the induction of less extreme dilatation, a faster return to baseline diameter (~20 min), and lower risk of side effects. In healthy volunteers, 8–35 µg GTN is estimated to induce a 4–10% dilation, without changes in blood pressure and heart rate.^{129,139} Furthermore, 25-µg GTN did not cause any significant increase in sympathetic signalling directed to muscle vasculature, evaluated by microneurography.¹⁴⁰ It has been suggested that higher GTN doses might be useful to assess maximum vasodilating capacity, thus providing information about structural alterations. However, maximal vasodilation cannot conceivably be obtained in these conditions because of counter-regulatory sympathetic vasoconstriction induced by the high doses of GTN. Although a low-dose GTN is recommended, this approach may not always be feasible, since low-dose GTN for oral use is not commercially available for most countries.

Glyceryl trinitrate should be administered >10 min after FMD testing to ensure return to baseline diameter. Furthermore, continuous diameter monitoring is recommended, because the timing of peak dilatation varies between subjects.¹⁴¹ The peak vasodilation response to GTN usually occurs between 4 and 5 min, both with high-^{141,142} and low-GTN doses.¹³⁷ Therefore, monitoring should be performed >5 min after GTN administration.

Conclusions

Flow-mediated dilation provides valuable and independent prognostic information. Unfortunately, different methodological approaches

importantly limit its validity, comparability, and its potential use as a clinical and physiological research tool. Indeed, adherence to guidelines and appropriate operator training improve FMD variability. Therefore, performing and reporting FMD according to state-of-the-art guidelines (see Table 2) is crucial to ensure valid conclusions and clinical evaluation. The application of state-of-the-art methodology allows examining whether the FMD correctly reclassifies individuals, adding incremental information to traditional CV risk factors. Finally, strict adherence to guidelines will also contribute to reference values, which will further improve the clinical applicability of FMD.

Supplementary material

Supplementary material is available at *European Heart Journal* online.

Conflict of interest: F.F. and L.G. reported to be shareholder of Quipu s.r.l as relevant financial activities outside the submitted work. The other authors have nothing to disclose.

References

- Townsend N, Nichols M, Scarborough P, Rayner M. Cardiovascular disease in Europe—epidemiological update 2015. *Eur Heart J* 2015;**36**:2696–2705.
- Timmis A, Townsend N, Gale C, Grobbee R, Maniadakis N, Flather M, Wilkins E, Wright L, Vos R, Bax J, Blum M, Pinto F, Vardas P; ESC Scientific Document Group. European Society of Cardiology: cardiovascular disease statistics 2017. *Eur Heart J* 2018;**39**:508–579.
- Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. *Nature* 1993;**362**:801–809.
- Green DJ, Hopman MT, Padilla J, Laughlin MH, Thijssen DH. Vascular adaptation to exercise in humans: role of hemodynamic stimuli. *Physiol Rev* 2017;**97**:495–528.
- Vanhoutte PM, Shimokawa H, Tang EH, Feletou M. Endothelial dysfunction and vascular disease. *Acta Physiol (Oxf)* 2009;**196**:193–222.
- Juonala M, Viikari JS, Laitinen T, Marniemi J, Helenius H, Ronnemaa T, Raitakari OT. Interrelations between brachial endothelial function and carotid intima-media thickness in young adults: the cardiovascular risk in young Finns study. *Circulation* 2004;**110**:2918–2923.
- Hallcox JP, Donald AE, Ellins E, Witte DR, Shipley MJ, Brunner EJ, Marmot MG, Deanfield JE. Endothelial function predicts progression of carotid intima-media thickness. *Circulation* 2009;**119**:1005–1012.
- Glowinska-Olszewska B, Tolwinski J, Urban M. Relationship between endothelial dysfunction, carotid artery intima media thickness and circulating markers of vascular inflammation in obese hypertensive children and adolescents. *J Pediatr Endocrinol Metab* 2007;**20**:1125–1136.
- Kobayashi K, Akishita M, Yu W, Hashimoto M, Ohni M, Toba K. Interrelationship between non-invasive measurements of atherosclerosis: flow-mediated dilation of brachial artery, carotid intima-media thickness and pulse wave velocity. *Atherosclerosis* 2004;**173**:13–18.
- Ross R. Atherosclerosis—an inflammatory disease. *N Engl J Med* 1999;**340**:115–126.
- Hurlimann D, Forster A, Noll G, Enseleit F, Chenevard R, Distler O, Bechir M, Spieker LE, Neidhart M, Michel BA, Gay RE, Luscher TF, Gay S, Ruschitzka F. Anti-tumor necrosis factor- α treatment improves endothelial function in patients with rheumatoid arthritis. *Circulation* 2002;**106**:2184–2187.
- Bilborough W, Keen H, Taylor A, O'Driscoll GJ, Arnold L, Green DJ. Anti-tumor necrosis factor- α therapy over conventional therapy improves endothelial function in adults with rheumatoid arthritis. *Rheumatol Int* 2006;**26**:1125–1131.
- Celermajer DS, Sorensen KE, Gooch VM, Spiegelhalter DJ, Miller OI, Sullivan ID, Lloyd JK, Deanfield JE. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. *Lancet* 1992;**340**:1111–1115.
- Flammer AJ, Anderson T, Celermajer DS, Creager MA, Deanfield J, Ganz P, Hamburg NM, Luscher TF, Shechter M, Taddei S, Vita JA, Lerman A. The assessment of endothelial function: from research into clinical practice. *Circulation* 2012;**126**:753–767.
- Ludmer PL, Selwyn AP, Shook TL, Wayne RR, Mudge GH, Alexander RW, Ganz P. Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. *N Engl J Med* 1986;**315**:1046–1051.
- Takase B, Hamabe A, Satomura K, Akima T, Uehata A, Ohsuzu F, Ishihara M, Kurita A. Close relationship between the vasodilator response to acetylcholine in the brachial and coronary artery in suspected coronary artery disease. *Int J Cardiol* 2005;**105**:58–66.
- Takase B, Uehata A, Akima T, Nagai T, Nishioka T, Hamabe A, Satomura K, Ohsuzu F, Kurita A. Endothelium-dependent flow-mediated vasodilation in coronary and brachial arteries in suspected coronary artery disease. *Am J Cardiol* 1998;**82**:1535–1539, A7–A8.
- Charakida M, Masi S, Luscher TF, Kastelein JJ, Deanfield JE. Assessment of atherosclerosis: the role of flow-mediated dilatation. *Eur Heart J* 2010;**31**:2854–2861.
- Rossi R, Nuzzo A, Olaru AI, Origliani G, Modena MG. Endothelial function affects early carotid atherosclerosis progression in hypertensive postmenopausal women. *J Hypertens* 2011;**29**:1136–1144.
- Yang Y, Xu JZ, Wang Y, Tang XF, Gao PJ. Brachial flow-mediated dilation predicts subclinical target organ damage progression in essential hypertensive patients: a 3-year follow-up study. *J Hypertens* 2014;**32**:2393–2400; discussion 2400.
- Patti G, Pasceri V, Melfi R, Goffredo C, Chello M, D'Ambrosio A, Montesanti R, Di Sciascio G. Impaired flow-mediated dilation and risk of restenosis in patients undergoing coronary stent implantation. *Circulation* 2005;**111**:70–75.
- Inaba Y, Chen JA, Bergmann SR. Prediction of future cardiovascular outcomes by flow-mediated vasodilatation of brachial artery: a meta-analysis. *Int J Cardiovasc Imaging* 2010;**26**:631–640.
- Ras RT, Streppel MT, Draijer R, Zock PL. Flow-mediated dilation and cardiovascular risk prediction: a systematic review with meta-analysis. *Int J Cardiol* 2013;**168**:344–351.
- Matsuzawa Y, Kwon TG, Lennon RJ, Lerman LO, Lerman A. Prognostic value of flow-mediated vasodilation in brachial artery and fingertip artery for cardiovascular events: a systematic review and meta-analysis. *J Am Heart Assoc* 2015;**4**: pii: e002270: 1–15.
- Xu Y, Arora RC, Hiebert BM, Lerner B, Szwajcer A, McDonald K, Rigatto C, Komenda P, Sood MM, Tangri N. Non-invasive endothelial function testing and the risk of adverse outcomes: a systematic review and meta-analysis. *Eur Heart J Cardiovasc Imaging* 2014;**15**:736–746.
- Green DJ, Jones H, Thijssen D, Cable NT, Atkinson G. Flow-mediated dilation and cardiovascular event prediction: does nitric oxide matter? *Hypertension* 2011;**57**:363–369.
- Peters SA, den Ruijter HM, Bots ML, Moons KG. Improvements in risk stratification for the occurrence of cardiovascular disease by imaging subclinical atherosclerosis: a systematic review. *Heart* 2012;**98**:177–184.
- Yeboah J, McClelland RL, Polonsky TS, Burke GL, Sibley CT, O'Leary D, Carr JJ, Goff DC, Greenland P, Herrington DM. Comparison of novel risk markers for improvement in cardiovascular risk assessment in intermediate-risk individuals. *JAMA* 2012;**308**:788–795.
- Ghiadoni L, Faia F, Salvetti M, Cordiano C, Biggi A, Puato M, Di Monaco A, De Sisti L, Volpe M, Ambrosio G, Gemignani V, Muiesan ML, Taddei S, Lanza GA, Cosentino F. Assessment of flow-mediated dilation reproducibility: a nationwide multicenter study. *J Hypertens* 2012;**30**:1399–1405.
- van Mil AC, Greyling A, Zock PL, Geleijnse JM, Hopman MT, Mensink RP, Reesink KD, Green DJ, Ghiadoni L, Thijssen DH. Impact of volunteer-related and methodology-related factors on the reproducibility of brachial artery flow-mediated vasodilation: analysis of 672 individual repeated measurements. *J Hypertens* 2016;**34**:1738–1745.
- Charakida M, de Groot E, Loukogeorgakis SP, Khan T, Luscher T, Kastelein JJ, Gasser T, Deanfield JE. Variability and reproducibility of flow-mediated dilatation in a multicentre clinical trial. *Eur Heart J* 2013;**34**:3501–3507.
- Vlachopoulos C, Xaplanteris P, Aboyans V, Brodmann M, Cifkova R, Cosentino F, De Carlo M, Gallino A, Landmesser U, Laurent S, Lekakis J, Mikhailidis DP, Naka KK, Protogerou AD, Rizzoni D, Schmidt-Trucksass A, Van Bortel L, Weber T, Yamashina A, Zimlichman R, Boutouyrie P, Cockcroft J, O'Rourke M, Park JB, Schillaci G, Sillesen H, Townsend RM. The role of vascular biomarkers for primary and secondary prevention. A position paper from the European Society of Cardiology Working Group on peripheral circulation: endorsed by the Association for Research into Arterial Structure and Physiology (ARTERY) Society. *Atherosclerosis* 2015;**241**:507–532.
- Goff DC Jr, Lloyd-Jones DM, Bennett G, Coady S, D'Agostino RB, Gibbons R, Greenland P, Lackland DT, Levy D, O'Donnell CJ, Robinson JG, Schwartz JS, Shero ST, Smith SC Jr, Sorlie P, Stone NJ, Wilson PW, Jordan HS, Nevo L, Wnek J, Anderson JL, Halperin JL, Albert NM, Bozkurt B, Brindis RG, Curtis LH, DeMets D, Hochman JS, Kovacs RJ, Ohman EM, Pressler SJ, Sellke FW, Shen WK, Smith SC Jr, Tomaselli GF; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *Circulation* 2014;**129**:S49–S73.

34. Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, Cooney MT, Corra U, Cosyns B, Deaton C, Graham I, Hall MS, Hobbs FDR, Lochen ML, Lollgen H, Marques-Vidal P, Perk J, Prescott E, Redon J, Richter DJ, Sattar N, Smulders Y, Tiberi M, van der Worp HB, van Dis I, Verschuren WMM, Binno S; ESC Scientific Document Group. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: the Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts). Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). *Eur Heart J* 2016;**37**:2315–2381.
35. Ghiadoni L, Taddei S, Virdis A. Hypertension and endothelial dysfunction: therapeutic approach. *Curr Vasc Pharmacol* 2012;**10**:42–60.
36. Luscher TF, Taddei S, Kaski JC, Jukema JW, Kallend D, Munzel T, Kastelein JJ, Deanfield JE, Dal VI. Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: the dal-VESSEL randomized clinical trial. *Eur Heart J* 2012;**33**:857–865.
37. Modena MG, Bonetti L, Coppi F, Bursi F, Rossi R. Prognostic role of reversible endothelial dysfunction in hypertensive postmenopausal women. *J Am Coll Cardiol* 2002;**40**:505–510.
38. Kitta Y, Obata JE, Nakamura T, Hirano M, Kodama Y, Fujioka D, Saito Y, Kawabata K, Sano K, Kobayashi T, Yano T, Nakamura K, Kugiyama K. Persistent impairment of endothelial vasomotor function has a negative impact on outcome in patients with coronary artery disease. *J Am Coll Cardiol* 2009;**53**:323–330.
39. Takishima I, Nakamura T, Hirano M, Kitta Y, Kobayashi T, Fujioka D, Saito Y, Watanabe K, Watanabe Y, Mishina H, Obata JE, Kawabata K, Tamaru S, Kugiyama K. Predictive value of serial assessment of endothelial function in chronic heart failure. *Int J Cardiol* 2012;**158**:417–422.
40. Bruno RM, Stea F, Sicari R, Ghiadoni L, Taddei S, Ungar A, Bonuccelli U, Tognoni G, Cintoli S, Del Turco S, Sbrana S, Gargani L, D'Angelo G, Pratali L, Berardi N, Maffei L, Picano E; Train the Brain Consortium. Vascular function is improved after an environmental enrichment program: the train the brain-mind the vessel study. *Hypertension* 2018;**71**:1218–1225.
41. Ras RT, Fuchs D, Koppenol WP, Garczarek U, Greyling A, Keicher C, Verhoeven C, Bouzamondo H, Wagner F, Trautwein EA. The effect of a low-fat spread with added plant sterols on vascular function markers: results of the Investigating Vascular Function Effects of Plant Sterols (INVEST) study. *Am J Clin Nutr* 2015;**101**:733–741.
42. Green DJ, Eijssvogels T, Bouts YM, Maiorana AJ, Naylor LH, Scholten RR, Spaanderman ME, Pugh CJ, Sprung VS, Schreuder T, Jones H, Cable T, Hopman MT, Thijssen DH. Exercise training and artery function in humans: nonresponse and its relationship to cardiovascular risk factors. *J Appl Physiol* 2014;**117**:345–352.
43. Wang TJ. Assessing the role of circulating, genetic, and imaging biomarkers in cardiovascular risk prediction. *Circulation* 2011;**123**:551–565.
44. Pignoli P, Tremoli E, Poli A, Oreste P, Paoletti R. Intimal plus medial thickness of the arterial wall: a direct measurement with ultrasound imaging. *Circulation* 1986;**74**:1399–1406.
45. Woodman RJ, Playford DA, Watts GF, Cheetham C, Reed C, Taylor RR, Puddey IB, Beilin LJ, Burke V, Mori TA, Green D. Improved analysis of brachial artery ultrasound using a novel edge-detection software system. *J Appl Physiol* 2001;**91**:929–937.
46. Gemignani V, Fatta F, Ghiadoni L, Poggianti E, Demi M. A system for real-time measurement of the brachial artery diameter in B-mode ultrasound images. *IEEE Trans Med Imaging* 2007;**26**:393–404.
47. Tomiyama H, Kohro T, Higashi Y, Takase B, Suzuki T, Ishizu T, Ueda S, Yamazaki T, Furumoto T, Kario K, Inoue T, Koba S, Watanabe K, Takemoto Y, Hano T, Sata M, Ishibashi Y, Node K, Maemura K, Ohya Y, Furukawa T, Ito H, Ikeda H, Yamashina A. Reliability of measurement of endothelial function across multiple institutions and establishment of reference values in Japanese. *Atherosclerosis* 2015;**242**:433–442.
48. Pyke KE, Tschakovsky ME. The relationship between shear stress and flow-mediated dilation: implications for the assessment of endothelial function. *J Physiol* 2005;**568**:357–369.
49. Pyke KE, Tschakovsky ME. Peak vs. total reactive hyperemia: which determines the magnitude of flow-mediated dilation? *J Appl Physiol* 2007;**102**:1510–1519.
50. Padilla J, Johnson BD, Newcomer SC, Wilhite DP, Mickleborough TD, Fly AD, Mather KJ, Wallace JP. Normalization of flow-mediated dilation to shear stress area under the curve eliminates the impact of variable hyperemic stimulus. *Cardiovasc Ultrasound* 2008;**6**:44.
51. Kremkau F. *Diagnostic Ultrasound Principles and Instruments*. Philadelphia, USA: Saunders; 2002.
52. Thrush A, Hartshorne T. *Peripheral Vascular Ultrasound*. How, Why and When. Amsterdam, The Netherlands: Elsevier; 2009.
53. Oates C. *Cardiovascular Haemodynamics and Doppler Waveforms Explained*. Cambridge, UK: Cambridge University Press; 2001.
54. Boot CR, Groothuis JT, Van Langen H, Hopman MT. Shear stress levels in paralyzed legs of spinal cord-injured individuals with and without nerve degeneration. *J Appl Physiol* 2002;**92**:2335–2340.
55. Gnasso A, Carallo C, Irace C, Spagnuolo V, De Novara G, Mattioli PL, Pujia A. Association between intima-media thickness and wall shear stress in common carotid arteries in healthy male subjects. *Circulation* 1996;**94**:3257–3262.
56. Parker BA, Trehearn TL, Meendering JR. Pick your poiseuille: normalizing the shear stimulus in studies of flow-mediated dilation. *J Appl Physiol* 2009;**107**:1357–1359.
57. Evans DH, Schlindwein FS, Levene MI. The relationship between time averaged intensity weighted mean velocity, and time averaged maximum velocity in neonatal cerebral arteries. *Ultrasound Med Biol* 1989;**15**:429–435.
58. Donald AE, Halcox JP, Charakida M, Story C, Wallace SM, Cole TJ, Friberg P, Deanfield JE. Methodological approaches to optimize reproducibility and power in clinical studies of flow-mediated dilation. *J Am Coll Cardiol* 2008;**51**:1959–1964.
59. Corretti MC, Anderson TJ, Benjamin EJ, Celermajer D, Charbonneau F, Creager MA, Deanfield J, Drexler H, Gerhard-Herman M, Herrington D, Vallance P, Vita J, Vogel R. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. *J Am Coll Cardiol* 2002;**39**:257–265.
60. Greyling A, van Mil AC, Zock PL, Green DJ, Ghiadoni L, Thijssen DH. Dilation T. Adherence to guidelines strongly improves reproducibility of brachial artery flow-mediated dilation. *Atherosclerosis* 2016;**248**:196–202.
61. Thijssen DH, Black MA, Pyke KE, Padilla J, Atkinson G, Harris RA, Parker B, Widlansky ME, Tschakovsky ME, Green DJ. Assessment of flow-mediated dilation in humans: a methodological and physiological guideline. *Am J Physiol Heart Circ Physiol* 2011;**300**:H2–H12.
62. Dawson EA, Green DJ, Cable NT, Thijssen DH. Effects of acute exercise on flow mediated dilation (FMD) in healthy humans. *J Appl Physiol* 2013;**115**:1589–1598.
63. Papamichael CM, Aznaouridis KA, Karatzis EN, Karatzi KN, Stamatiopoulos KS, Vamvakou G, Lekakis JP, Mavrikakis ME. Effect of coffee on endothelial function in healthy subjects: the role of caffeine. *Clin Sci (Lond)* 2005;**109**:55–60.
64. Hijmering ML, Stroes ES, Olijhoek J, Hutten BA, Blankestijn PJ, Rabelink TJ. Sympathetic activation markedly reduces endothelium-dependent, flow-mediated vasodilation. *J Am Coll Cardiol* 2002;**39**:683–688.
65. Craiem D, Chironi G, Garipey J, Miranda-Lacet J, Levenson J, Simon A. New monitoring software for larger clinical application of brachial artery flow-mediated vasodilatation measurements. *J Hypertens* 2007;**25**:133–140.
66. Thijssen DH, de Groot P, Kooijman M, Smits P, Hopman MT. Sympathetic nervous system contributes to the age-related impairment of flow-mediated dilation of the superficial femoral artery. *Am J Physiol Heart Circ Physiol* 2006;**291**:H3122–H3129.
67. Ghiadoni L, Donald AE, Cropley M, Mullen MJ, Oakley G, Taylor M, O'Connor G, Betteridge J, Klein N, Steptoe A, Deanfield JE. Mental stress induces transient endothelial dysfunction in humans. *Circulation* 2000;**102**:2473–2478.
68. Williams MR, Westerman RA, Kingwell BA, Paige J, Blombery PA, Sudhir K, Komesaroff PA. Variations in endothelial function and arterial compliance during the menstrual cycle. *J Clin Endocrinol Metab* 2001;**86**:5389–5395.
69. ter Avest E, Holveijn S, Stalenhoef AF, de Graaf J. Variation in non-invasive measurements of vascular function in healthy volunteers during daytime. *Clin Sci (Lond)* 2005;**108**:425–431.
70. Donald AE, Charakida M, Falaschetti E, Lawlor DA, Halcox JP, Golding J, Hingorani AD, Smith GD, Deanfield JE. Determinants of vascular phenotype in a large childhood population: the Avon Longitudinal Study of Parents and Children (ALSPAC). *Eur Heart J* 2010;**31**:1502–1510.
71. Widlansky ME, Vita JA, Keyes MJ, Larson MG, Hamburg NM, Levy D, Mitchell GF, Osypuk EW, Vasan RS, Benjamin EJ. Relation of season and temperature to endothelium-dependent flow-mediated vasodilation in subjects without clinical evidence of cardiovascular disease (from the Framingham Heart Study). *Am J Cardiol* 2007;**100**:518–523.
72. Briet M, Collin C, Laurent S, Tan A, Azizi M, Agharazii M, Jeunemaitre X, Alhenc-Gelas F, Boutouyrie P. Endothelial function and chronic exposure to air pollution in normal male subjects. *Hypertension* 2007;**50**:970–976.
73. Naylor LH, Weisbrod CJ, O'Driscoll G, Green DJ. Measuring peripheral resistance and conduit arterial structure in humans using Doppler ultrasound. *J Appl Physiol* 2005;**98**:2311–2315.
74. Doshi SN, Naka KK, Payne N, Jones CJ, Ashton M, Lewis MJ, Goodfellow J. Flow-mediated dilatation following wrist and upper arm occlusion in humans: the contribution of nitric oxide. *Clin Sci (Lond)* 2001;**101**:629–635.
75. Green DJ, Dawson EA, Groenewoud HM, Jones H, Thijssen DH. Is flow-mediated dilation nitric oxide mediated? A meta-analysis. *Hypertension* 2014;**63**:376–382.

76. Mullen MJ, Kharbanda RK, Cross J, Donald AE, Taylor M, Vallance P, Deanfield JE, MacAllister RJ. Heterogeneous nature of flow-mediated dilatation in human conduit arteries in vivo: relevance to endothelial dysfunction in hypercholesterolemia. *Circ Res* 2001;**88**:145–151.
77. Berry KL, Skyrme-Jones RA, Meredith IT. Occlusion cuff position is an important determinant of the time course and magnitude of human brachial artery flow-mediated dilation. *Clin Sci (Lond)* 2000;**99**:261–267.
78. Gori T, Dragoni S, Lisi M, Di Stolfo G, Sonnati S, Fineschi M, Parker JD. Conduit artery constriction mediated by low flow. A novel non-invasive method for the assessment of vascular function. *J Am Coll Cardiol* 2008;**51**:1953–1958.
79. Dawson EA, Alkarmi A, Thijssen DH, Rathore S, Marsman DE, Cable NT, Wright DJ, Green DJ. Low-flow mediated constriction is endothelium-dependent: effects of exercise training after radial artery catheterization. *Circ Cardiovasc Interv* 2012;**5**:713–719.
80. Gori T, Muxel S, Damaske A, Radmacher MC, Fasola F, Schaefer S, Schulz A, Jabs A, Parker JD, Munzel T. Endothelial function assessment: flow-mediated dilation and constriction provide different and complementary information on the presence of coronary artery disease. *Eur Heart J* 2012;**33**:363–371.
81. Weissgerber TL, Davies GA, Tschakovsky ME. Low flow-mediated constriction occurs in the radial but not the brachial artery in healthy pregnant and nonpregnant women. *J Appl Physiol* 2010;**108**:1097–1105.
82. Parker BA, Ridout SJ, Proctor DN. Age and flow-mediated dilation: a comparison of dilatory responsiveness in the brachial and popliteal arteries. *Am J Physiol Heart Circ Physiol* 2006;**291**:H3043–H3049.
83. Thijssen DH, van Bommel MM, Bullens LM, Dawson EA, Hopkins ND, Tinken TM, Black MA, Hopman MT, Cable NT, Green DJ. The impact of baseline diameter on flow-mediated dilation differs in young and older humans. *Am J Physiol Heart Circ Physiol* 2008;**295**:H1594–H1598.
84. Atkinson G, Batterham AM. Allometric scaling of diameter change in the original flow-mediated dilation protocol. *Atherosclerosis* 2013;**226**:425–427.
85. Silber HA, Ouyang P, Bluemke DA, Gupta SN, Foo TK, Lima JA. Why is flow-mediated dilation dependent on arterial size? Assessment of the shear stimulus using phase-contrast magnetic resonance imaging. *Am J Physiol Heart Circ Physiol* 2005;**288**:H822–H828.
86. Yeboah J, Crouse JR, Hsu FC, Burke GL, Herrington DM. Brachial flow-mediated dilation predicts incident cardiovascular events in older adults: the Cardiovascular Health Study. *Circulation* 2007;**115**:2390–2397.
87. van den Munckhof I, Scholten R, Cable NT, Hopman MT, Green DJ, Thijssen DH. Impact of age and sex on carotid and peripheral arterial wall thickness in humans. *Acta Physiol* 2012;**206**:220–228.
88. Atkinson G, Batterham AM, Thijssen DH, Green DJ. A new approach to improve the specificity of flow-mediated dilation for indicating endothelial function in cardiovascular research. *J Hypertens* 2013;**31**:287–291.
89. Leeson P, Thorne S, Donald A, Mullen M, Clarkson P, Deanfield J. Non-invasive measurement of endothelial function: effect on brachial artery dilatation of graded endothelial dependent and independent stimuli. *Heart* 1997;**78**:22–27.
90. Black MA, Cable NT, Thijssen DH, Green DJ. Importance of measuring the time course of flow-mediated dilatation in humans. *Hypertension* 2008;**51**:203–210.
91. Liuni A, Luca MC, Lisi M, Dragoni S, Di Stolfo G, Mariani JA, Uxa A, Gori T, Parker JD. Observations of time-based measures of flow-mediated dilation of forearm conduit arteries: implications for the accurate assessment of endothelial function. *Am J Physiol Heart Circ Physiol* 2010;**299**:H939–H945.
92. Padilla J, Johnson BD, Newcomer SC, Wilhite DP, Mickleborough TD, Fly AD, Mather KJ, Wallace JP. Adjusting flow-mediated dilation for shear stress stimulus allows demonstration of endothelial dysfunction in a population with moderate cardiovascular risk. *J Vasc Res* 2009;**46**:592–600.
93. Thijssen DH, Tinken TM, Hopkins N, Dawson EA, Cable NT, Green DJ. The impact of exercise training on the diameter dilator response to forearm ischemia in healthy men. *Acta Physiol (Oxf)* 2011;**201**:427–434.
94. Laughlin MH, Turk JR, Schrage WG, Woodman CR, Price EM. Influence of coronary artery diameter on eNOS protein content. *Am J Physiol Heart Circ Physiol* 2003;**284**:H1307–H1312.
95. Thijssen DH, Dawson EA, Black MA, Hopman MT, Cable NT, Green DJ. Heterogeneity in conduit artery function in humans: impact of arterial size. *Am J Physiol Heart Circ Physiol* 2008;**295**:H1927–H1934.
96. Gemignani V, Bianchini E, Faïta F, Giannarelli C, Plantinga Y, Ghiadoni L, Demi M. Ultrasound measurement of the brachial artery flow-mediated dilation without ECG gating. *Ultrasound Med Biol* 2008;**34**:385–391.
97. Kizhakekuttu TJ, Guterman DD, Phillips SA, Jurva JW, Arthur EI, Das E, Widlansky ME. Measuring FMD in the brachial artery: how important is QRS gating? *J Appl Physiol* 2010;**109**:959–965.
98. Carter HH, Dawson EA, Birk GK, Spence AL, Naylor LH, Cable NT, Thijssen DH, Green DJ. Effect of SR manipulation on conduit artery dilation in humans. *Hypertension* 2013;**61**:143–150.
99. Pyke KE, Dwyer EM, Tschakovsky ME. Impact of controlling shear rate on flow-mediated dilation responses in the brachial artery of humans. *J Appl Physiol* 2004;**97**:499–508.
100. Anderson EA, Mark AL. Flow-mediated and reflex changes in large peripheral artery tone in humans. *Circulation* 1989;**79**:93–100.
101. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. *Nature* 1980;**288**:373–376.
102. de Groot PC, Poelkens F, Kooijman M, Hopman MT. Preserved flow-mediated dilation in the inactive legs of spinal cord-injured individuals. *Am J Physiol Heart Circ Physiol* 2004;**287**:H374–H380.
103. Atkinson G, Batterham AM, Black MA, Cable NT, Hopkins ND, Dawson EA, Thijssen DH, Jones H, Tinken TM, Green DJ. Is the ratio of flow-mediated dilation and shear rate a statistically sound approach to normalization in cross-sectional studies on endothelial function? *J Appl Physiol* 2009;**107**:1893–1899.
104. Betik AC, Luckham VB, Hughson RL. Flow-mediated dilation in human brachial artery after different circulatory occlusion conditions. *Am J Physiol* 2004;**286**:442–448.
105. Thijssen DH, Bullens LM, van Bommel MM, Dawson EA, Hopkins N, Tinken TM, Black MA, Hopman MT, Cable NT, Green DJ. Does arterial shear explain the magnitude of flow-mediated dilation? A comparison between young and older humans. *Am J Physiol Heart Circ Physiol* 2009;**296**:H57–H64.
106. Harris RA, Padilla J. Proper “normalization” of flow-mediated dilation for shear. *J Appl Physiol* 2007;**103**:1108; author reply 1109.
107. Atkinson G, Batterham AM. The percentage flow-mediated dilation index: a large-sample investigation of its appropriateness, potential for bias and causal nexus in vascular medicine. *Vasc Med* 2013;**18**:354–365.
108. Atkinson G. Shear rate normalization is not essential for removing the dependency of flow-mediated dilation on baseline artery diameter: past research revisited. *Physiol Meas* 2014;**35**:1825–1835.
109. Mitchell GF, Parise H, Vita JA, Larson MG, Warner E, Keaney JF Jr, Keyes MJ, Levy D, Vasan RS, Benjamin EJ. Local shear stress and brachial artery flow-mediated dilation: the Framingham Heart Study. *Hypertension* 2004;**44**:134–139.
110. Philpott AC, Lonn E, Title LM, Verma S, Buthieu J, Charbonneau F, Anderson TJ. Comparison of new measures of vascular function to flow mediated dilatation as a measure of cardiovascular risk factors. *Am J Cardiol* 2009;**103**:1610–1615.
111. Huang AL, Silver AE, Shvenke E, Schopfer DW, Jahangir E, Titas MA, Shpilman A, Menzoian JO, Watkins MT, Raffetto JD, Gibbons G, Woodson J, Shaw PM, Dhady M, Eberhardt RT, Keaney JF Jr, Gokce N, Vita JA. Predictive value of reactive hyperemia for cardiovascular events in patients with peripheral arterial disease undergoing vascular surgery. *Arterioscler Thromb Vasc Biol* 2007;**27**:2113–2119.
112. Paine NJ, Hinderliter AL, Blumenthal JA, Adams KF, Sueta CA, Chang PP, O'Connor CM, Sherwood A. Reactive hyperemia is associated with adverse clinical outcomes in heart failure. *Am Heart J* 2016;**178**:108–114.
113. Celermajer DS, Sorensen KE, Bull C, Robinson J, Deanfield JE. Endothelium-dependent dilation in the systemic arteries of asymptomatic subjects relates to coronary risk factors and their interaction. *J Am Coll Cardiol* 1994;**24**:1468–1474.
114. Williamson EB, Bronas UG, Dengel DR. Automated edge detection versus manual edge measurement in analysis of brachial artery reactivity: a comparison study. *Ultrasound Med Biol* 2008;**34**:1499–1503.
115. Harris RA, Nishiyama SK, Wray DW, Richardson RS. Ultrasound assessment of flow-mediated dilation. *Hypertension* 2010;**55**:1075–1085.
116. Mancini GB, Yeoh E, Abbott D, Chan S. Validation of an automated method for assessing brachial artery endothelial dysfunction. *Can J Cardiol* 2002;**18**:259–262.
117. Preik M, Lauer T, Heiss C, Tabery S, Strauer BE, Kelm M. Automated ultrasonic measurement of human arteries for the determination of endothelial function. *Ultraschall Med* 2000;**21**:195–198.
118. Sonka M, Liang W, Lauer RM. Automated analysis of brachial ultrasound image sequences: early detection of cardiovascular disease via surrogates of endothelial function. *IEEE Trans Med Imaging* 2002;**21**:1271–1279.
119. Steinbuch J, Hoeks AP, Hermeling E, Truijman MT, Schreuder FH, Mess WH. Standard B-mode ultrasound measures local carotid artery characteristics as reliably as radiofrequency phase tracking in symptomatic carotid artery patients. *Ultrasound Med Biol* 2016;**42**:586–595.
120. Faïta F, Masi S, Loukogeorgakis S, Gemignani V, Okorie M, Bianchini E, Charakida M, Demi M, Ghiadoni L, Deanfield JE. Comparison of two automatic methods for the assessment of brachial artery flow-mediated dilation. *J Hypertens* 2011;**29**:85–90.
121. Greyling A, van Mil AC, Zock PL, Green DJ, Ghiadoni L, Thijssen DH, Dilation T. Assessing the perceived quality of brachial artery flow mediated dilation studies for inclusion in meta-analyses and systematic reviews: description of data employed in the development of a scoring: tool based on currently accepted guidelines. *Data Brief* 2016;**8**:73–77.

122. Herrington DM, Fan L, Drum M, Riley WA, Pusser BE, Crouse JR, Burke GL, McBurnie MA, Morgan TM, Espeland MA. Brachial flow-mediated vasodilator responses in population-based research: methods, reproducibility and effects of age, gender and baseline diameter. *J Cardiovasc Risk* 2001;**8**:319–328.
123. Simova I, Nossikoff A, Denchev S. Interobserver and intraobserver variability of flow-mediated vasodilatation of the brachial artery. *Echocardiography* 2008;**25**:77–83.
124. Witte DR, van der Graaf Y, Grobbee DE, Bots ML, Group SS. Measurement of flow-mediated dilatation of the brachial artery is affected by local elastic vessel wall properties in high-risk patients. *Atherosclerosis* 2005;**182**:323–330.
125. Vanoli D, Wiklund U, Lindqvist P, Henein M, Naslund U. Successful novice's training in obtaining accurate assessment of carotid IMT using an automated ultrasound system. *Eur Heart J Cardiovasc Imaging* 2014;**15**:637–642.
126. Bruno RM, Ghiadoni L. Vascular smooth muscle function: defining the diabetic vascular phenotype. *Diabetologia* 2013;**56**:2107–2109.
127. Joannides R, Haefeli WE, Linder L, Richard V, Bakali EH, Thuillez C, Luscher TF. Nitric oxide is responsible for flow-dependent dilatation of human peripheral conduit arteries in vivo. *Circulation* 1995;**91**:1314–1319.
128. Joannides R, Richard V, Haefeli WE, Benoist A, Linder L, Lüscher TF, Thuillez C. Role of nitric oxide in the regulation of the mechanical properties of peripheral conduit arteries in humans. *Hypertension* 1997;**30**:1465–1470.
129. Maruhashi T, Soga J, Fujimura N, Idei N, Mikami S, Iwamoto Y, Kajikawa M, Matsumoto T, Hidaka T, Kihara Y, Chayama K, Noma K, Nakashima A, Goto C, Higashi Y. Nitroglycerine-induced vasodilation for assessment of vascular function: a comparison with flow-mediated vasodilation. *Arterioscler Thromb Vasc Biol* 2013;**33**:1401–1408.
130. Montero D, Walther G, Perez-Martin A, Vicente-Salar N, Roche E, Vinet A. Vascular smooth muscle function in type 2 diabetes mellitus: a systematic review and meta-analysis. *Diabetologia* 2013;**56**:2122–2133.
131. Fontes-Guerra PC, Cardoso CR, Muxfeldt ES, Salles GF. Nitroglycerin-mediated, but not flow-mediated vasodilation, is associated with blunted nocturnal blood pressure fall in patients with resistant hypertension. *J Hypertens* 2015;**33**:1666–1675.
132. Kullo IJ, Malik AR, Bielak LF, Sheedy PF 2nd, Turner ST, Peyser PA. Brachial artery diameter and vasodilator response to nitroglycerine, but not flow-mediated dilatation, are associated with the presence and quantity of coronary artery calcium in asymptomatic adults. *Clin Sci (Lond)* 2007;**112**:175–182.
133. Malik AR, Sultan S, Turner ST, Kullo IJ. Urinary albumin excretion is associated with impaired flow- and nitroglycerin-mediated brachial artery dilatation in hypertensive adults. *J Hum Hypertens* 2007;**21**:231–238.
134. Morimoto S, Yurugi T, Aota Y, Sakuma T, Jo F, Nishikawa M, Iwasaka T, Maki K. Prognostic significance of ankle-brachial index, brachial-ankle pulse wave velocity, flow-mediated dilation, and nitroglycerin-mediated dilation in end-stage renal disease. *Am J Nephrol* 2009;**30**:55–63.
135. Akamatsu D, Sato A, Goto H, Watanabe T, Hashimoto M, Shimizu T, Sugawara H, Sato H, Nakano Y, Miura T, Zukeran T, Serizawa F, Hamada Y, Tsuchida K, Tsuji I, Satomi S. Nitroglycerin-mediated vasodilatation of the brachial artery may predict long-term cardiovascular events irrespective of the presence of atherosclerotic disease. *J Atheroscler Thromb* 2010;**17**:1266–1274.
136. Ducharme A, Dupuis J, McNicoll S, Harel F, Tardif JC. Comparison of nitroglycerin lingual spray and sublingual tablet on time of onset and duration of brachial artery vasodilation in normal subjects. *Am J Cardiol* 1999;**84**:952–954, A8.
137. Ghiadoni L, Huang Y, Magagna A, Buralli S, Taddei S, Salvetti A. Effect of acute blood pressure reduction on endothelial function in the brachial artery of patients with essential hypertension. *J Hypertens* 2001;**19**:547–551.
138. Deanfield J, Donald A, Ferri C, Giannattasio C, Halcox J, Halligan S, Lerman A, Mancina G, Oliver JJ, Pessina AC, Rizzoni D, Rossi GP, Salvetti A, Schiffrin EL, Taddei S, Webb DJ. Endothelial function and dysfunction. Part I: methodological issues for assessment in the different vascular beds: a statement by the Working Group on Endothelin and Endothelial Factors of the European Society of Hypertension. *J Hypertens* 2005;**23**:7–17.
139. Oliver JJ, Bowler A, Beudeker Q, Cate T, Webb DJ. Dose-response relationship of sublingual nitroglycerin with brachial artery dilatation and change in central and peripheral augmentation index. *Clin Pharmacol Ther* 2005;**77**:337–338.
140. Ghiadoni L, Taddei S, Bruno RM. Hemodynamic and autonomic effects of low-dose glyceryl trinitrate used to test endothelium-independent vasodilation of the brachial artery. *Artery Res* 2017;**20**:85.
141. Bressler B, Chan S, Mancini GB. Temporal response of brachial artery dilation after occlusion and nitroglycerin. *Am J Cardiol* 2000;**85**:396–400, A10.
142. Thelen AM, Kelly AS, Williamson EB, Dengel DR. Examining the time course of endothelium-independent dilation by nitroglycerin. *Ultrasound Med Biol* 2008;**34**:1217–1220.